I
Phase 1
First-in-human and early safety. The visits are different; the operational standard is not.
Experience
Seven sites. 50+ studies. The work is specific.
More than six years in clinical research across Phases I–IV, including protocols that do not behave like a standard visit schedule.
6+
Years in research
7
Investigator sites
50+
Studies executed
I–IV
Phases in scope
Phases
Phases I through IV. One operational standard.
II
Phase 2
Signal, dose, and the day-to-day discipline of a live protocol.
III
Phase 3
Pivotal execution: enrollment, consistency, and a file that will be read.
IV
Phase 4
Post-marketing and observational programs. Closeout does not get lighter.
Therapeutic areas
Nine areas. More than fifty studies.
Confidentiality keeps client names and protocol numbers off this page.
Oncology
Neurology
Gastroenterology
Vaccines
Pulmonology
Dermatology
Cardiology
Pain
Gene therapy
Selected indications
Alzheimer’s · Crohn’s · Eosinophilic esophagitis · Breast cancer · Lung cancer · COPD · Asthma · Psoriasis · Eczema · Immunizations — among others.
Advanced protocols
The studies that do not run on a standard playbook.
First-in-human work, specialized handling, longer visit architectures, chain of identity. Gene therapy sits in that book. The closeout standard does not change.
Talk through a protocol